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We recently reported proliferating cell nuclear antigen (PCNA) as a ligand for the NK cell activating receptor, NKp44,
which unexpectedly triggers inhibition. The recognition of nuclear proteins such as PCNA, by related NK cell receptors
has been reported. Widespread upregulation of PCNA in tumor cells may therefore promote immune evasion.
Introduction
Natural killer (NK) cells provide primary
innate immune defense against cancer,
and natural cytotoxic receptors (NCRs)
are key activating receptors for tumor
recognition. The purpose of our recent
study was to identify and characterize
tumor associated ligands for the NCR,
NKp44.
1 It is currently believed that
tumors that survive immune surveillance
have developed mechanisms to evade
the immune system.
2 Proliferating cell
nuclear antigen (PCNA) is commonly
overexpressed in cancer cells, where it
contributes to cellular proliferation and
transformation.
3 We recently showed that
the interaction of NKp44 with target
cell-expressed PCNA paradoxically inhi-
bits NK cell function. We further demon-
strated that PCNA promotes tumor
survival by suppressing NK activation
through the immunoreceptor tyrosine-
based inhibitory motif (ITIM) on the
NKp44 cytoplasmic domain. Finally, we
observed that nuclear/cytoplasmic PCNA
from target cells is recruited to the NK
immunological synapse (NKIS) when
NKp44 is expressed on the NK cells.
Results
Direct binding of NKp44 to PCNA.
Using recombinant soluble chimeric NK
cell receptors fused to the human IgG Fc
domain, we showed that PCNA protein
manifests binding to NKp44 but not
to other NK cell receptors, including
LIR1, NKG2D, KIR2DL4, NKp30 and
NKp46. Immunoprecipitation studies
also confirmed that NKp44 interacts
with soluble PCNA and native PCNA
from cell lysates, while LIR1 does not.
Using surface plasmon resonance analysis,
NKp44 displayed a characteristic receptor-
ligand binding affinity to PCNA
(KD = 3.4  10
29 M).
Target PCNA downregulates NK cell
functions. We next expressed PCNA-
GFP in HeLa target cells and showed that
PCNA overexpression suppressed IFNc
secretion and lysis by NKp44-expressing
NK cells. In addition, incubation of
NKp44-expressing NK cells (NK92-44)
with blocking anti-NKp44 antibodies
abolished the inhibition of lysis.
We further investigated the effect of
endogenous PCNA-downregulation using
an siRNA approach. Downregulation of
PCNA in PANC-1 (pancreas), MCF-7
(breast), DU145 (prostate), HeLa (cervix),
and U251 (brain) tumor cells resulted
in enhanced lysis by NK92-44 cells.
Downregulation of endogenous PCNA in
target cancer cells also enhanced IFNc
secretion by NKp44-expressing NK cells,
whereas responses by NKp44
null NKL cells
were unaffected.
PCNA inhibits NK cells function
through the ITIM on NKp44. We further
tested whether this PCNA-mediated
inhibition might involve the ITIM located
in the cytoplasmic tail of NKp44. We
employed NK-92 cells transduced to
express a form of NKp44 in which the
cytoplasmic tail is either truncated prior
to the ITIM or mutated at the tyrosine
site within the ITIM. In this setting, the
overexpression of PCNA resulted in signi-
ficantly reduced functions of NK92 cells
expressing wild type, as compared with
*Correspondence to: Angel Porgador; Email: angel@bgu.ac.il
Submitted: 01/12/12; Accepted: 01/13/12
http://dx.doi.org/10.4161/onci.19366
OncoImmunology 1:4, 572–574; July 2012; G 2012 Landes Bioscience
572 OncoImmunology Volume 1 Issue 4© 2012 Landes Bioscience.
Do not distribute.
the mutated forms of NKp44. Thus, the
integrity of the ITIM on the NKp44
cytoplasmic domain is essential for the
PCNA-mediated inhibitory effect on
NK cells.
PCNA recruitment to the NK immune
synapse. We also studied whether soluble
PCNA, target cell-conditioned medium,
or exosomal fractions could mediate
PCNA inhibition of NK cell function.
None of these conditions could mimic
inhibition of NK cell function by PCNA-
expressing target cells. On the contrary, a
direct interaction between the NK cell and
the target cell was found to be imperative
for PCNA-mediated effects, both in vitro
and in vivo. Furthermore, using live
imaging confocal microscopy, we showed
that PCNA in the tumor target cell can
be recruited to the NKIS, and that this
recruitment correlates with a high surface
density of NKp44 on the conjugated
NK cell.
Discussion
The overexpression of PCNA by tumor
cells strongly correlates with cancer viru-
lence, since PCNA contributes to many
survival processes, including DNA replica-
tion, DNA repair, and cell-cycle pro-
gression.
3 Our data suggest that PCNA
may additionally promote tumor survival
by promoting immune evasion through
NKp44-mediated inhibition of NK cell
attack. Although PCNA is primarily a
nuclear/cytoplasmic factor, other cyto-
plasmic or nuclear proteins have been
shown to serve as ligands to membrane-
associated NCRs, notably the NKp30
ligands, CMV-pp65 and nuclear BAT3,
4,5
and the NKp46 ligand, vimentin.
6 Collec-
tively, these observations suggest that the
localization of NCR ligands need not be
primarily restricted to the membrane.
We further hypothesize that the PCNA-
NKp44 interaction may also contribute to
fetal protection from maternal NK cells
during pregnancy. Interestingly, PCNA is
overexpressed in decidual tissue, and
maternal-derived decidual NK cells con-
stitutively express NKp44.
7 During the
first trimester of pregnancy, these decidual
NK cells comprise 50% to 90% of the
lymphoid cells in the decidua, and they
are tolerized toward the fetal tissue.
7
Interestingly, this NK cell tolerance corre-
lates with PCNA overexpression in fetal-
derived trophoblast cells during the first
trimester.
8 Therefore, PCNA-induced
inhibition through NKp44 may also
contribute to the immune tolerance of
maternal NK cells during pregnancy.
Although PCNA has not been pre-
viously reported to localize at the plasma
membrane, we observed its accumulation
at the contact interface with NKp44-
expressing NK cells, which is commonly
called the NKIS. PCNA was recently
shown to interact with the membrane-
associated protein, Annexin A2 (ANXA2),
9
which was also recently identified as a
potential cell surface tumor antigen.
10
Although yet untested, we speculate that
ANXA2 may play a role in recruiting
PCNA to the NKIS upon interaction of a
tumor cell with NKp44-expressing NK
cells (Fig.1).
To summarize, this work identifies a
new ligand for NKp44, demonstrates a
novel inhibitory signaling function for
NKp44, reveals a previously unrecognized
mechanism of immune evasion, and re-
emphasizes the role of nuclear proteins as
important ligands for NCRs.
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Figure1. Model of the proposed interaction of NKp44 with PCNA. (1) The interaction with NK cells
initiates the movement of PCNA within tumor target cells toward the immunological synapse.
PCNA migration within the tumor cell may be initiated by the physical interaction between
the NK cell and target cell or the lytic state of other tumor cells attacked by NK cells. (2) Movement
of PCNA from the nucleus or the cytoplasm toward the immunological synapse. (3) It is possible
that PCNA is carried to or anchored at the membrane by ANXA2. (4) PCNA interacts with NKp44
in the NKIS. (5) The interaction with PCNA uncharacteristically initiates dominant ITIM-mediated
inhibitory signaling, which is distinct from the previously-recognized activation signaling of NKp44.
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